634. Clinical efficacy of new neuraminidase inhibitors, laninamivir and peramivir in patients with seasonal influenza; a randomized clinical trial
Session: Poster Abstract Session: Oh, Those Pesky Viruses!
Thursday, October 27, 2016
Room: Poster Hall
  • idweek2016.pdf (168.8 kB)
  • Background: Influenza is a major viral infection that spreads worldwide and is currently treated with neuraminidase inhibitors. Of these, peramivir and laninamivir are currently available in limited countries, and clinical efficacies of these drugs are remained to be undetermined. 

    Methods: we conducted the randomized clinical trial during the winter season in Japan.Fifty-one outpatients with seasonal influenza during the 2013-2014 and the 2014-2015 winter season were randomly assigned to one of three treatment groups, and received either oseltamivir (75 mg twice daily for 5 days), laninamivir (40 mg once), or peramivir (300 mg once). The diagnosis for influenza was made by a rapid antigen test. The course of the symptoms; fever, coughing, throat soaring, nasal discharge, headache, muscle pains, joint pains, nausea/vomiting, and diarrhea was collected by using a questionnaire. Data regarding demographics, medical history, and complications were collected as background data. The endpoints of this study were the time to defervescence and the time of disappearance of other clinical symptoms after administration of neuraminidase inhibitors. Student's t-test and Fisher’s exact test were used for statistical analysis. 

    Results: Thirty-four patients (oseltamivir group; n=9, laninamivir group; n=12, peramivir group; n=13) could be followed up. There were no significant differences in background data, and symptoms on the admission of all groups. There were significant differences between the peramivir and oseltamivir groups with respect to the time to defervescence (average ± standard error; 1.00 ± 0.23 days vs 2.67 ± 0.37 days). There were no significant differences between the laninamivir and each other groups with respect to defervescence. However, that average time in the laninamivir group (1.58 ± 0.36 days) was shorter than that in the oseltamivir group. There were no significant differences between each group with respect to the time of disappearance of other symptoms.

    Conclusion: The clinical efficacy of peramivir is superior to that of oseltamivir. Although there was no significant difference between laninamivir group and oseltamivir group with respect to the time to defervescence, the clinical value of laninamivir also might be superior because laninamivir has an advantage over oseltamivir with respect to medication adherence.

    Yusuke Yoshino, M.D., Kazunori Seo, M.D., Ichiro Koga, M.D., Takatoshi Kitazawa, M.D. and Yasuo Ota, M.D., Infectious Diseases, Teikyo University School of Medicine, Tokyo, Japan


    Y. Yoshino, None

    K. Seo, None

    I. Koga, None

    T. Kitazawa, None

    Y. Ota, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.